AxoGen (NASDAQ:AXGN – Get Free Report) and Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, risk, valuation and institutional ownership.
Earnings & Valuation
This table compares AxoGen and Fresenius SE & Co.”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| AxoGen | $225.21 million | 10.57 | -$15.70 million | ($0.68) | -65.09 |
| Fresenius SE & Co. | $25.87 billion | 1.13 | $1.43 billion | $0.79 | 16.35 |
Profitability
This table compares AxoGen and Fresenius SE & Co.’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| AxoGen | -13.36% | -8.90% | -6.47% |
| Fresenius SE & Co. | 6.67% | 10.33% | 4.87% |
Insider & Institutional Ownership
80.3% of AxoGen shares are owned by institutional investors. 2.4% of AxoGen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Analyst Ratings
This is a summary of recent ratings and target prices for AxoGen and Fresenius SE & Co., as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| AxoGen | 1 | 1 | 10 | 0 | 2.75 |
| Fresenius SE & Co. | 0 | 0 | 3 | 0 | 3.00 |
AxoGen presently has a consensus price target of $51.56, indicating a potential upside of 16.48%. Given AxoGen’s higher probable upside, equities research analysts plainly believe AxoGen is more favorable than Fresenius SE & Co..
Risk and Volatility
AxoGen has a beta of 1.16, meaning that its stock price is 16% more volatile than the S&P 500. Comparatively, Fresenius SE & Co. has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500.
Summary
Fresenius SE & Co. beats AxoGen on 8 of the 14 factors compared between the two stocks.
About AxoGen
AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.
About Fresenius SE & Co.
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.
